Jeffrey P. Ward, M.D., Ph.D.

Assistant Professor
Internal Medicine
Oncology

Cancer Biology Program
Immunology Program

  • 314-747-7409

  • 9934 Wohl Clinic

  • jward2@wustl.edu

  • Identification of tumor specific mutant antigens recognized by the immune system as foreign that serve as the target of a T-cell response against tumors

Research Abstract:

The clinical development and successful introduction into practice of immune checkpoint inhibitors that reinvigorate a patient's own immune cells to target tumors have revolutionized the treatment paradigm for those with lung cancer. However, the fact remains that many patients will not benefit from current cancer immunotherapies, and a better understanding of the interactions between lymphocytes, tumor cells, and the cells that make up the tumor microenvironment will be required to move towards the next generation of therapeutics.

My research focuses on the identification of tumor specific mutant antigens recognized by the immune system as foreign that serve as the target of a T-cell response against tumors. We take advantage of cancer genomics and bioinformatics techniques to detect tumor-specific mutations that accumulate during transformation and use this information to predict which mutations are potentially antigenic. We then use these predictions to validate those that elicit T-cell responses. In preclinical models, personalized vaccines targeting neoantigens trigger potent anti-tumor immune responses leading to rejection of established tumors, providing proof of principle that a similar strategy may prove successful for patients.

Selected Publications:

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, Rech AJ, Zaretsky JM, Comin-Anduix B, Ng AHC, Chour W, Yu TV, Rizvi H, Chen JM, Manning P, Steiner GM, Doan XC, Merghoub T, Guinney J, Kolom A, Selinsky C, Ribas A, Hellmann MD, Hacohen N, Sette A, Heath JR, Bhardwaj N, Ramsdell F, Schreiber RD, Schumacher TN, Kvistborg P, Defranoux NA
Cell 2020 Oct 29;183(3):818-834e13

CDC1 Prime and Are Licensed by CD4(+) T Cells to Induce Anti-Tumour Immunity
Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JT 4th, Bagadia P, Liu T, Briseno CG, Li L, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, Schreiber RD, Murphy KM
Nature 2020 Aug;584(7822):624-629

MHC-II Neoantigens Shape Tumour Immunity and Response to Immunotherapy
Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, Runci D, Ward JP, Gubin MM, Medrano RFV, Arthur CD, White JM, Sheehan KCF, Chen A, Wucherpfennig KW, Jacks T, Unanue ER, Artyomov MN, Schreiber RD
Nature 2019 Oct;574(7780):696-701

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D
Clin Cancer Res 2019 Oct 15;25(20):6119-6126

High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling During Successful Immune-Checkpoint Cancer Therapy
Gubin MM*, Esaulova E*, Ward JP*, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN
Cell 2018 Nov 15;175(5):1443
(*contributed equally)

Checkpoint Blockade Immunotherapy Reshapes the High-Dimensional Phenotypic Heterogeneity of Murine Intratumoural Neoantigen-Specific CD8(+) T Cells
Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW
Nat Commun 2017 Sep 15;8(1):562

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, Schreiber RD
Cancer Immunol Res 2017 Feb;5(2):106-117

CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes With NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells
Davis ZB, Sowrirajan B, Cogswell A, Ward JP, Planelles V, Barker E
AIDS Res Hum Retroviruses 2017 Feb;33(2):93-100

Last Updated: 2/9/2021 5:08:13 PM

Back To Top

Follow us: